Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine.
² Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Dermatology, University of California, San Diego, La Jolla, CA, USA.

Morgan Birabaharan et al. Br J Dermatol. 2022 Aug.

. 2022 Aug;187(2):271-273.

doi: 10.1111/bjd.21240. Epub 2022 May 24.

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine.
² Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
³ Department of Dermatology, University of California, San Diego, La Jolla, CA, USA.

No abstract available

References

1. Tomayko MM, Damsky W, Fathy R et al. Subepidermal blistering eruptions, including bullous pemphigoid, following COVID‐19 vaccination. J Allergy Clin Immunol 2021; 148:750–1. - PMC - PubMed
1. Gambichler T, Hamdani N, Budde H et al. Bullous pemphigoid after SARS‐CoV‐2 vaccination: spike protein‐directed immunofluorescence confocal microscopy and T‐cell‐receptor studies. Br J Dermatol 2021; 186:728–31. - PMC - PubMed
1. Hsu D, Brieva J, Nardone B et al. Validation of database search strategies for the epidemiological study of pemphigus and pemphigoid. Br J Dermatol 2016; 174:645–8. - PMC - PubMed
1. Bastuji‐Garin S, Joly P, Lemordant P et al. Risk factors for bullous pemphigoid in the elderly: a prospective case‐control study. J Invest Dermatol 2011; 131:637–43. - PubMed
1. Lee SG, Lee HJ, Yoon MS et al. Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes. JAMA Dermatol 2019; 155:172–7. - PMC - PubMed